久久亚洲国产熟女精品免费,黄色视频在线观看视频在线观看,色污无遮挡在线看WWW

日韩爱爱无码免费看_天美传奇MV在线高清_国产成人av无码一区在线播_国产午夜理论大片a级毛片_韩国美女VIP一区二区_亚洲伊人五月丁香激情_亚洲熟女老逼视频_大学生无套白浆视频

Product Pipeline

Domain		Product	Indication
Pulmonary Diseases	Fibrosis-associated	ETUARY? (Pirfenidone)	Idiopathic Pulmonary Fibrosis(IPF)
Pulmonary Diseases	Fibrosis-associated	ETUARY? (Pirfenidone)	Pneumoconiosis
Pulmonary Diseases	Fibrosis-associated	ETUARY? (Pirfenidone)	Radiation-Induced Lung Injury With or Without Immune-Related Pneumonitis
Pulmonary Diseases	Fibrosis-associated	ETUARY? (Pirfenidone)	Dermatomyositis Interstitial Lung disease (DM-ILD)
Pulmonary Diseases	Fibrosis-associated	ETUARY? (Pirfenidone)	Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Pulmonary Diseases	Others	F528(Novel Anti-inflammatory Small Molecule Drug)	Chronic Obstructive Pulmonary Disease(COPD)
Pulmonary Diseases	Others	F230(Selective endothelin receptor antagonist)	Pulmonary Arterial Hypertension (PAH)
Liver Diseases	Fibrosis	F351 (Hydronidone)	Chronic Hepatitis B Liver Fibrosis
Liver Diseases	Other	F573(Caspase protease inhibitor)	Acute Liver Failure (ALF) / Acute-on-Chronic Liver Failure (ACLF)
Kidney Disease	Fibrosis Associated	ETUARY? (Pirfenidone)	Diabetic Kidney Disease (DKD)

Rare Disease

R&D Centers

Our R&D Department is comprised of Drug Discovery, CMC (Chemistry, Manufacturing, and Control), Clinical Development, Medical Affairs, and Regulatory Affairs.

Drug Discovery

During the drug discovery stage, we explore new R&D opportunities, conduct feasibility research and provide evaluation for the opportunities. We also design and prepare new chemical compounds, conduct systematic research related to the manufacturing process and quality management of the new drugs, and develop technology platforms to support, manage and supervise the related technologies. Our R&D centers support a targeted drug discovery and screening platform, which can efficiently complete target identification and validation, compound design, lead optimization and IND approval application.

Chemistry, Manufacture & Controls (CMC)

The CMC Group is a critical link between discovery and clinical study. It is responsible for developing chemical and pharmaceutical processes, so that drug substance can be made with the desired physical and chemical properties, and formulated to achieve maximum bio-availability and stability. During the CMC stage, the synthesis of each API molecule is investigated thoroughly to ensure that the drug substance can reach pre-determined quality standards, the manufacturing processes are safe, robust, economical, and environmental friendly, and the drug products have good stability and suitable storage conditions and shelf-life.

Clinical Development

Our clinical development team oversees clinical trials for drug development, sets up the procedural standard of clinical affairs, and handles clinical medicine matters. Our clinical development team also focuses on clinical development strategy development, clinical trial protocol design, clinical trial operation coordination, pharmacovigilance, and clinical trial quality control. Our clinical development team members specialized in management of all stages of our clinical trials, including clinical trial design, implementation, drug supply, and the collection and analysis of trial data. We collaborate with top clinical experts in various areas as our principal investigators, leverage the operational capabilities of industry-leading CROs, and rely on well-known academic medical institutions and clinical trial centers in China and abroad to promote the high-quality and efficient implementation of our clinical trials in China.

Medical Affairs

Our medical affair group focus on the follow-up research on the therapeutic effect of marketed products, collection of patients’ feedback and exploration of the potential indication expansion. Internally, the medical affair team bridges the information gap between our drug R&D team and sales and marketing force, and assists the sales and marketing team to prepare educational materials to accurately describe the differentiation and superiority of our products. Externally, our medical affair team communicate our research data and clinical evidence to KOLs and physicians to support our academic promotion.

Regulatory Affairs

Our regulatory affairs group is responsible for the regulatory approval process of our drug candidates, including, addressing inquiries from relevant authorities and monitoring our R&D projects to ensure their compliance with relevant regulations. Our regulatory affairs team manages the regulatory submission process for our drug candidates, according to the filing and approval requirements by the relevant authorities before clinical trials and commercialization. The regulatory affairs team prepares and manages regulatory filings, addresses regulatory questions and conducts CMC and GMP readiness assessments for our drug candidates. We possess extensive knowledge and experience with regard to regulatory filings in China.

R&D Team

Gyre Pharmaceuticals has a professional R&D team. There are nearly half of team members owned more than 10 years R&D experience. The key R&D team members are doctor with oversea study background, and scientists with abundant R&D experience. They developed several Class 1.1 new drugs with profound professional attainments and international concept vision.

We identify suitable drug development targets and carry out project evaluation and overall project design based on our development strategies, and explore and establish experimental methodology by coordinating among the different experimental platforms. We carefully select drug development programs by balancing the commercial potential of each drug candidate and its likelihood of successful development, its potential competition and market size.

We consistently devote resources to research and development to pave for long-term growth. We believe the diversification and expansion of our product pipeline through both in-house research and development and through external collaboration are critical to our long-term competitiveness and success.